CalciMedica, Inc. CALC
We are a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Our product candidates target calcium release-activated calcium ("CRAC") channels and, if approved, would represent a new class of therapeutics.
Clinical and preclinical data suggest that inhibition of CRAC channels may have therapeutic potential through a dual mechanism involving modulation of inflammatory signaling and protection of tissue cells from calcium-mediated injury. Dysregulated CRAC channel signaling has been implicated in a range of acute and chronic diseases characterized by immune activation, inflammation, and cellular injury. We seek to leverage our CRAC channel inhibitor platform to develop therapies for indications in which these pathways are clinically relevant.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| R&D | $15.2M | $14.5M | $15.9M | $8.3M | $18.9M | $21.0M | $30.6M | — |
| SG&A | $7.9M | $9.7M | $22.2M | $5.8M | $17.0M | $8.9M | $6.9M | — |
| Total operating expenses | $23.1M | $24.2M | $38.1M | $14.2M | $35.9M | $29.8M | $37.5M | — |
| Operating income | -$23.1M | -$24.2M | -$38.1M | -$14.2M | -$35.9M | -$29.8M | -$37.5M | — |
| Interest expense | $1.4M | $0 | — | — | — | — | — | — |
| Pre-tax income | -$29.6M | -$13.7M | -$34.4M | -$7.8M | — | — | — | — |
| Income tax | $0 | $0 | $1.0K | $1.0K | — | — | — | — |
| Net income | -$29.6M | -$13.7M | -$34.4M | -$7.8M | -$35.8M | -$27.5M | -$37.0M | — |
| EPS, basic | -1.97 | -1.22 | -7.66 | -111.16 | -1.69 | — | — | — |
| EPS, diluted | -1.97 | -1.22 | -7.66 | -111.16 | -1.69 | -5.25 | -33.41 | — |
| Shares, diluted (wtd. avg.) | $15.0M | $11.2M | $4.5M | $82.2K | $21.2M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $11.5M | $7.9M | $5.5M | $1.3M | $13.4M | $33.4M | $15.9M | — |
| Short-term investments | $1.5M | $10.7M | $5.7M | $0 | $50.3M | $61.6M | $20.1M | — |
| Total current assets | $13.5M | $19.7M | $11.6M | $1.7M | $67.1M | $99.2M | $36.3M | — |
| Property, plant and equipment | $50.0K | $119.0K | $167.0K | $147.0K | $2.0M | $1.9M | $2.0M | — |
| Total assets | $13.6M | $19.8M | $12.2M | $3.3M | $69.1M | $101.8M | $40.7M | — |
| Accounts payable | $1.2M | $2.0M | $1.4M | $2.9M | $527.0K | $2.5M | $4.6M | — |
| Total current liabilities | $3.8M | $3.7M | $4.0M | $4.8M | $4.1M | $7.0M | $12.3M | — |
| Total liabilities | $20.2M | $5.4M | $4.0M | $12.6M | $4.1M | $7.0M | $12.3M | — |
| Retained earnings | -$189.3M | -$159.8M | -$146.1M | -$111.7M | -$169.2M | -$133.4M | -$105.8M | — |
| Total equity | -$6.6M | $14.4M | $8.2M | -$71.3M | -$64.0M | $94.8M | -$103.0M | -$66.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21.2M | -$21.1M | -$25.7M | -$11.8M | -$31.5M | -$32.1M | -$31.2M | — |
| Depreciation and amortisation | $46.0K | $58.0K | $58.0K | $52.0K | $519.0K | $395.0K | $303.0K | — |
| Stock-based compensation | $3.0M | $2.3M | $12.0M | $1.8M | $5.4M | $1.8M | $738.0K | — |
| Capital expenditure | $28.0K | $8.0K | $78.0K | $4.0K | $488.0K | $1.0M | $605.0K | — |
| Investing cash flow | $9.6M | -$4.4M | $8.9M | -$4.0K | $10.8M | -$42.6M | -$20.6M | — |
| Financing cash flow | $15.2M | $28.0M | $20.9M | $8.5M | $695.0K | $92.2M | $54.9M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-314085.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |